Antibiotic exposure, Clostridium difficile toxins, and spore formation are key factors involved in the pathogenesis of Clostridium difficile infection (CDI). A high incidence of CDI due to toxin A-B+ strains, which were classified into two genotypes (ST81 and ST37) by multilocus sequence typing, was identified in Beijing Friendship Hospital in 2016-2017. ST81 was the most prevalent type, accounting for 81.25% of toxin A-B+ strains. ST81 corresponded to a novel PCR ribotype, PKI-017, with one less band than ST37/ribotype 017 in PCR ribotyping. All ST81 strains showed a high level of ciprofloxacin resistance (MICs ≥ 64 μg mL −1 ) and moxifloxacin resistance (MICs ≥ 128 μg mL −1 ) with the amino acid substitutions Thr82
INTRODUCTION
Clostridium difficile is a Gram-positive, spore-forming anaerobic bacillus that causes enteric diseases, ranging from mild diarrhea to severe pseudomembranous colitis (Goudarzi et al. 2014; Tariq and Khanna 2017) . The pathogenicity of C. difficile is dependent on the release of two exotoxins, toxin A (enterotoxin) and toxin B (cytotoxin). Toxin A-B+ strains fail to produce toxin A due to a 1.8 kb deletion of the repetitive domain of the tcdA gene (Kato et al. 1999) . To assess the individual role of toxin A and toxin B in disease, hamster models of C. difficile infection (CDI) were established by the construction of isogenic tcdA and tcdB mutants of a virulent C. difficile strain (Lyras et al. 2009; Carter, Rood and Lyras 2010; Carter et al. 2015) . It suggested that toxin B, similar to toxin A, was essential for virulence of C. difficile, and independently leads to serious diseases. Many clinical studies have revealed that the phenotype toxin A-B+ strains caused symptomatic CDI, severe pseudomembranous colitis (PMC), and even hospital outbreaks in Canada, the Netherlands and Poland (Al-Barrak et al. 1999; Alfa et al. 2000; Pituch et al. 2001) . In Asia, several studies indicated that toxin A-B+ strains had induced fatal diseases and nosocomial outbreaks in Japan and South Korea (Toyokawa et al. 2003; Kim et al. 2008; Owens et al. 2008) . The few studies from China reported regional variations in the frequencies of toxin A-B+ strains from 16.8% to 46.6% (Huang et al. 2009; Chen et al. 2014; Cheng et al. 2016) .
To understand the spread of bacteria and define the epidemic clones, several molecular genotyping methods, such as multilocus sequence typing (MLST), polymerase chain reaction (PCR) ribotyping and toxinotyping, have been applied to evaluate C. difficile (Rupnik et al. 1997; Stubbs et al. 1999; Lemée and Pons 2010) . Currently, a total of eight variant toxinotypes are known in toxin A-B+ strains. Several toxinotypes of toxin A-B+ strains, which produce the third toxin known as C. difficile binary toxin (CDT) that is encoded by two binary toxin genes, cdtA and cdtB, are denominated tcdA-B+ CDT+ strains (Rupnik et al. 2003) . The genotype tcdA-B+CDT+ strains have been reported in Japan, South Korea and Australia (Rupnik et al. 2003; Shin et al. 2008; Elliott et al. 2011) . However, little is known about the toxin A-B+ strains in China that have been identified by toxinotyping. Previous studies reported that toxin A-B+ strains were classed as ST37/ribotype 017, which was regarded as one of the prevalent types in China (Hawkey et al. 2013; Du et al. 2014; Jin et al. 2017) . In the last two years, we collected 109 toxigenic C. difficile isolates from one thousand inpatients with antibiotic-associated diarrhea in Beijing Friendship hospital. We found that toxin A-B+ strains accounted for 29.36% of the total. Of the toxin A-B+ strains, MLST identified two sequence types (STs): ST81 and ST37. The most frequent type, ST81, accounted for 81.25% of all the toxin A-B+ strains, while ST37 strains had a small proportion in the toxin A-B+ strains. However, the reason for the dominance of ST81 was not clear.
Importantly, antibiotic exposure during hospitalization is the foremost risk factor for CDI. The clone isolates belonging to the ST37/ribtpye 017 were resistant to fluoroquinolones, resulting in an outbreak of CDI in hospital (Drudy et al. 2006; Drudy et al. 2007 ). The antimicrobial susceptibility patterns for fluoroquinolones and the relative resistance mechanism for ST81 strains have yet to be completely elucidated. In addition, a major hurdle to effective treatment of CDI is the formation of C. difficile spores which can persist on contaminated surfaces in clinical settings, leading to inpatient transmission and a relapse of CDI in medical institutions (Owens et al. 2008; Al-Hinai, Jones and Papoutsakis 2015) .
The aim of this study was to elucidate the difference and relationship between ST81 and ST37 strains using molecular typing methods (PCR ribotyping and toxinotyping) and phylogenetic analysis, to analyse the differences in fluoroquinolone resistance patterns, toxin B production and spore formation ability between the ST81 and ST37 strains.
MATERIALS AND METHODS

Bacterial strains
A total of 32 toxin A-B+ strains were obtained from inpatients with antibiotic-associated diarrhea in different wards of the Beijing Friendship hospital of Capital Medical University during 2016-2017. Twenty-six of these isolates belonged to ST81 and six strains belonged to ST37. The isolates were confirmed by matrix-assisted laser desorption/ionization time-offlight mass spectrometry (MALDI-TOF-MS) (VITEK MS, France). One C. difficile strain ST1/ribotype 027 was used as a positive control for detecting the toxin genes and binary toxin genes, cdtA and cdtB.
Antimicrobial susceptibility test, amplification and sequencing of the gyrA and gyrB genes
The minimum inhibitory concentrations (MICs) of ciprofloxacin and moxifloxacin were determined by the reference agar dilution method according to 2017 Clinical and Laboratory Standards Institute (CLSI) guidelines. The MIC interpretive breakpoints of ciprofloxacin were referenced for moxifloxacin (susceptible, ≤ 2 μg mL −1 ; intermediate, 4 μg mL −1 ; resistant, ≥ 8 μg mL −1 ). The quinolone resistance-determining regions (QRDR) of gyrA and gyrB were amplified as previously reported (Dridi et al. 2002) . The PCR products were purified and sequenced with an automatic DNA sequencer ABI 3700. Sequences were aligned with the reference sequence of C. difficile 630 (GenBank accession no. NC 009089.1) using DNA MAN alignment software.
Detection of toxin genes by PCR
Genomic DNA was extracted using a Bacterial Genomic DNA Extraction Kit (Takara, Japan). Firstly, four different primers for PCR amplification of toxin genes tcdA and tcdB, and binary toxin genes cdtA and cdtB, were performed as previously described (Kato et al. 1998; Persson, Torpdahl and Olsen 2008) . The primers for the tcdA gene were derived from the partial non-repeating sequence (Non-rep) of the tcdA gene, which could effectively distinguish positive toxigenic strains from negative nontoxigenic strains. Secondly, PCR was performed using primers NK11 and NK9 as previously described (Kato et al. 1998) . The primers NK11 and NK9 were amplified for the repeating region (rep) of the tcdA gene and the segment of the PCR product of approximately 700 bp was designated as the toxin A-B+ strain.
PCR ribotyping
PCR ribotyping that targeted the 16S-23S rRNA gene intergenic spacer region of C. difficile was performed as previously described . PCR ribotypes that differed from the reference patterns by at least one band were assigned a novel PCR ribotype and marked with the prefix RKI (Arvand et al. 2009; Zaiss et al. 2009 ).
Toxinotyping
The isolates were characterized by the toxinotyping method previously reported (Rupnik et al. 1997) . Briefly, two PCR fragments B1 and A3 were used for analysing the toxinotypes. B1 PCR fragments were digested with two restriction enzymes, HincII and AccI, and the A3 amplified products were cut with one restriction enzyme, EcoRI. In this study, the PCR reaction conditions were optimized for increasing efficiency and reducing the amplification time. The thermal cycles of B1 and A3 PCR were: initial denaturation at 98
• C for 30 s, followed by 35 cycles of denaturation at 98
• C for 20 s, annealing at 56
• C for 2 min and extension at 72
• C for 1 min, before finishing at 72
• C for 10 min. PCR fragments were visualized on 1.0% agarose, the fragment size standard was a DL2000 ladder (Solarbio, China). The toxinotype was identified according to the combination of restriction patterns in PCR fragments BI and A3 from the website of Clostridium difficile toxinotypes (http://www.mf.um.si/mf/tox/).
Phylogenetic analysis of ST81 and ST37
The relationship between ST81 and ST37 was analysed using the concatenated sequences of the seven MLST loci (adk, atpA, dxr, glyA, recA, soda and tpi) to construct a neighbour-joining tree using MEGA 7.0 software. Other ST types we collected were also analysed for evolutionary and genetic diversity. The evolutionary distance was computed using the Maximum Composite Likelihood method, according to the units of the number of base substitutions per site.
Quantitative real-time PCR analysis of tcdB, tcdC and spoA RNA Total RNA was extracted from bacteria using a MiniBEST Universal RNA Extraction kit (Takara, Japan). The RNA concentration was assessed with a NanoDrop 2000 spectrophotometer (Thermo, USA). For complementary DNA (cDNA) synthesis, 1 μg of total RNA was reverse transcribed into cDNA using a PrimeScriptTM cDNA Synthesis Kit (Takara, Japan). Different primers for amplifying the specific sequences of tcdB, tcdC, spoA and 16S rRNA genes were used as previously reported (Vohra and Poxton 2011) and the 16S rRNA gene was selected as a reference. Quantitative real-time PCR was performed in a total volume of 20 μL for each reaction, which contained 2 μL of cDNA (100 ng), 0.6 μL of 10 μ mol L −1 primer (forward or reverse), 0. Toxin production, Vero cell cytotoxicity and toxin neutralization assays, and viable cells activity assays C. difficile bacteria were cultured anaerobically in brain heart infusion broth for 48 h. Culture supernatants were obtained by centrifugation at 12 000 rpm for 1 min, filtered and stored at -80 • C. The toxin B production of 300 μL of filtered C. difficile culture supernatants was measured with a VIDAS C. difficile toxin A&B kit using mini VIDAS (BioMerieux SA, France). Vero cells (10 4 cells mL −1 ) were seeded in 96-well culture plates (Costar, USA) in Eagle minimal essential medium (MEM, Invitrogen, USA) supplemented with 10% heat-inactivated fetal bovine serum (Invitrogen, USA) in a 5% humidified CO 2 incubator. The culture medium of each well was changed into 100 μL Eagle minimal essential medium without serum until cells reached confluency. Next, 10 μL of filtered C. difficile culture supernatants were pre-incubated with equal volumes of a 1:100 concentration of anti-toxin B (RD, USA) or anti-toxin A serum (Novus, USA) for 1 h at 37
• C, then 10 μL of filtered C. difficile culture supernatants with or without anti-toxin serum was added to the Vero cells. After incubating for 48 h at 37
• C, the cytopathogenic effects were observed by inverse microscopy. If the cytopathogenic effects could be neutralized by anti-toxin B antiserum, the results were considered positive. Then, cell viability in the Vero cell cytotoxicity assays was further determined using cell counting kit-8 (CCK-8, Japan). Cells in a 96-well plate were incubated in an incubator for 3 h after adding 10 μL of CCK-8 solution and the optical density was measured at 450 nm with a microplate reader (SpectraMax M3, Molecular Devices, USA).
Spore production
Twenty-six ST81 strains and six ST37 strains were cultured anaerobically in brain heart infusion broth for 24 h and adjusted to approximately 0.5 McFarland standard. Then, 500 μL of 0.5 McFarland standard bacteria were transferred to 5 mL of brain heart broth and cultured anaerobically for 72 h. Pellets were obtained by centrifugation at 4000 rpm for 10 min and treated with 5 mL 95% ethanol for 1 h at room temperature. After washing twice in distilled water, the pellets were suspended in 5 mL of 0.01 M sterile phosphate buffered saline solution. After 100-fold dilutions, 100 μL volumes were plated onto brain heart infusion agar plates containing 0.1% sodium taurocholate and incubated anaerobically for 48 h. The colonies in the culture dishes were counted and the number of spores per milliliter of culture was calculated.
Statistical analysis
Student's t-test (using a two-tailed paired t-test) was used to evaluate the significant difference of two groups; all data were expressed as the mean ± standard deviation (SD). Each experiment was repeated three times independently and P < 0.05 was considered statistically significant.
RESULTS
The diverse results of PCR ribotyping and toxinotyping
For toxin gene PCR assays, all ST81 and ST 37 strains were identified as toxin A-B+ strains; binary toxin genes were not detected (Table S1 in the supplementary data, Fig. 2 ). PCR ribotype profiles ( Fig. 1) indicated that there was only one different band (approximately 300 bp in size) in ST81 strains compared with ST37 strains. PCR ribotyping analysis identified that all the ST37 strains were the same genotype PCR ribotype 017, while the ST81 strains could not be assigned to any known PCR ribotype and were designated as a new PCR ribotype PKI-017. But, ST81 and ST37 strains were both classified as toxinotype VIII by toxinotyping ( Fig. 2B-C , Table S1 ).
Phylogenetic relationships between ST81 and ST37
ST81 was a combination of seven allelic profiles (adk3, atpA1, dxr3, glyA8, recA6, soda 9 and tpi11) and the MLST scheme of ST37 was adk3, atpA7, dxr3, glyA8, recA6, soda 9 and tpi11. There was only a single allelic difference (atpA) with four variable nucleotide sites between ST81 and ST37. ST81 and ST37 were clustered as a clone complex and were closely related genetically (Fig. 3) . 
The significant differences of both MICs for ciprofloxacin and moxifloxacin, and the relative resistance mechanisms between ST81 strains and ST37 strains
As shown in Table 1 , compared with ST37 strains, all ST81 strains showed high-level resistance to ciprofloxacin (MICs ≥ 64 μg mL −1 ) and moxifloxacin (MICs ≥ 128 μg mL −1 ), and had one amino acid substitution, Thr82 to Ile in GyrA, and one amino acid mutation, Asp426 to Val in GyrB. Six ST37 strains had various MICs of ciprofloxacin and moxifloxacin ranging from 4 μg mL −1 to 64 μg mL −1 and 4 μg mL −1 to 16 μg mL −1 , respectively.
One of the six ST37 strains was intermediate in susceptibility to ciprofloxacin and moxifloxacin (MICs, 4 μg mL −1 ) with no amino acid change in GyrA or GyrB, and five out of six ST37 strains had one amino acid change, Thr82 to Ile, in GyrA.
Analysis of the relative RNA expression of tcdB and tcdC
A comparison of the relative RNA expression of tcdB and tcdC of ST81 and ST37 strains is shown in Fig. 4A . The RNA relative gene expression of tcdB in ST81 strains was one half lower than in ST37 strains (P ≤ 0.01), while the relative gene expression of tcdC in ST81 strains was higher than in ST37 strains (P ≤ 0.01). and ST37 strains, respectively; lanes 6 to 7, AccI restricted pattern of ST81 and ST37 strains, respectively). The size marker used was a DL2000 ladder.
Toxin production, Vero cell cytotoxicity and viable cell activity assays
As shown in Fig. 4B , ST81 strains produced approximately two times less toxin B than the ST37 strains (P ≤ 0.01). Vero cell cytotoxicity and toxin neutralization assays (Fig. 4D) confirmed that the filtered culture supernatants of both ST81 and ST37 strains resulted in cytopathogenic effects; round cells that exceeded 90% of the total cells were observed. Cell cytotoxicity was neutralized by incubation with anti-toxin B antibodies. In contrast, cell cytotoxicity was not affected by incubation with anti-toxin A antibodies. Vero cell cytotoxicity assays using CCK-8 demonstrated that after separate treatment with the filtered culture supernatants of ST81 and ST37 strains, the percentage of viable cells for the ST81 group was higher than that for the ST37 group (P ≤ 0.05) (Fig. 4C) .
Analysis of the relative RNA expression of spoA and spore production detection
As shown in Fig. 5A , the spoA RNA relative gene expression of ST81 strains was much higher than that of ST37 strains (P ≤ 0.01). Similarly, the number of spores ST81 strains produced was significantly higher than the ST37 strains (P ≤ 0.01) (Fig. 5B ).
DISCUSSION
In this study, we first described the differences and relationships between a new emerging genotype C. difficile ST81 and C. difficile ST37 using molecular typing, fluoroquinolone susceptibility tests and the relative molecular resistance mechanism, toxin gene expression and toxin production, and spore formation ability. We chose only toxin A-B+ strains to ensure the accuracy of tests and to avoid interference from toxin A when detecting the level of toxin B production and in Vero cell cytotoxicity tests. Toxin A-B+ strains of C. difficile, which caused enterotoxin inflammatory reaction in a rabbit ileal loop test, were reported in the early 1990s (Borriello et al. 1992; Lyerly et al. 1992; Brazier, Stubbs and Duerden 1999) . Since Kato et al. 1998 designed the PCR primer pair NK11 and NK9 (derived from repeating sequences of the tcdA gene) to differentiate toxin A-B+ strains from toxin A+B+ strains. In our previous research, we found that toxin A-B+ strains made up a large proportion of CDI. MLST molecular type analysis indicated that there were only two sequence types in toxin A-B+ strains and ST81 was the major type. This prompted us to investigate the characteristics of this special genotype ST81. Despite ST81 and ST37 strains being identified with the same toxinotype VIII by toxinotyping, PCR ribotyping identified ST81 and ST37 as belonging to separate types, which implied that genetic diversity existed in the two types. Phylogenetic analysis indicated that ST81 and ST37 were more closely related genetically, compared with other toxin A+B+ strains. Fluoroquinolones inhibit bacterial growth by disrupting the enzyme responsible for negative DNA supercoiling, DNA gyrase A and/or DNA gyrase B (Aldred, Kerns and Osheroff 2014) . Mutations in the gyrA and/or gyrB genes within the quinolone resistance-determining region lead to reduced affinity for the drug by alteration of the drug target. Various amino acid substitutions have been identified in the GyrA subunit and/or the GyrB subunit in fluoroquinolone-resistant C. difficile strains (Spigaglia 2016) . In this research, we found that ST37 strains had a single amino acid substitution Thr82 to Ile in GyrA, which was different from a previous report which stated that ST37 strains showed an amino acid substitution Asp 426 to Val in GyrB (Drudy et al. 2006) . In addition, we observed that there were obvious differences in amino acid mutations between ST81 and ST37 strains by sequence analysis of both GyrA and GyrB. ST37 strains had either no mutation or a single amino acid substitution, Thr82 to Ile in GyrA. ST81 strains showed both a single amino acid substitution, Thr82 to Ile in GyrA, and an amino acid substitution, Asp 426 to Val in GyrB. Furthermore, MICs of ciprofloxacin and moxifloxacin for ST81 strains were much higher than those for ST37 strains. It is probable that amino acid substitution both in GyrA and GyrB had a synergistic effect in conferring high-level fluoroquinolone resistance. In our hospital, moxifloxacin is widely used in the treatment of a wide variety of human infections such as respiratory, urinary tract and intestinal infections. The increased use of moxifloxacin may be an important risk factor for CDI caused by ST81 strains dependent on their high-level resistance to moxifloxacin. ST81 strains can easily colonize and proliferate in the intestinal tract after fluoroquinolone antibiotic treatment.
Both the relative expression level of tcdB RNA and toxin B protein in ST81 strains were lower than in ST37 strains. Conversely, the relative gene expression of tcdC in ST81 strains was higher than in ST37 strains. TcdC that located the PaLoc of toxigenic C. difficile isolates was regarded as a negative regulatory factor suppressing the gene expression of tcdB and toxin B production (Hundsberger et al. 1997) . This implied that the lower tcdB gene and protein toxin B expression in ST81 strains were due to negative regulation of tcdC. Although toxin B production of ST81 strains was lower, the filtered supernatant of ST81 strains caused Vero cells to become round and disrupted cell-to-cell contact, which was distinguishable from the cell morphology as discrete clusters described in other reports (Borriello et al. 1992; Kato et al. 1998) . These results suggested that various cell cytotoxicity effects existed among the different types of toxin A-B+ strains.
Sporulation is the key trait of C. difficile that enables it to persist, spread and generate potential transmission in hospital environments. The master regulator of endospore formers (spo0A) activates the onset of sporulation (de Hoon, Eichenberger and Vitkup 2010; Talukdar et al. 2015) . Compared to ST37 strains, the higher level transcription of spo0A gene in ST81 strains may increase the expression of downstream genes involved in the sporulation pathway, resulting in a greater number of spores being produced. Consistently, we observed that the number of Comparison of cytotoxic effects of the toxin tcdB from ST81 and ST37 strains on Vero cells. These data represented the mean of three independent determinations ± standard deviation (SD). Two groups with significant differences were marked with * P < 0.05 and * * P < 0.01.
spores in ST81 strains were significantly higher than in ST37 strains, which suggested that ST81 strains would survive better than ST37 strains in unfavourable environmental conditions or inside hosts for a long time, enabling transmission to other hosts or environments. In conclusion, high-level fluoroquinolone resistance of C. difficile ST81 strains may be a factor that contributes to the persistence and dissemination of this genotype in the hospital environment, since the use of moxifloxacin is increasing in our hospital. ST81 strains had a higher production of spores resistant to a variety of treatments including heat, UV radiation and oxidizing agents, and therefore easily mediated the transmission of C. difficile by healthcare workers or inpatients in the healthcare facilities. Once patients develop CDI caused by ST81 strains, after receiving the antibiotics in our hospital they need to be transferred to other hospitals with infections such as AIDS or tuberculosis. These patients may affect the other inpatients by close contact in the same departments, causing the spread and transmission of ST81 strains to other hospitals. Despite ST81 strains producing lower levels of toxin B this still results in cytopathic effects in Vero cells using a cytotoxicity assay, demonstrating that toxin B was essential for disease pathogenesis. Further investigations of the relationships between ST81 strains with clinical features, the severity of CDI and the relapse of CDI are required. In short, the emergence of the C. difficile genotype ST81 with high-level fluoroquinolone resistance and high spore-formation ability is of importance in continuously monitoring probable nosocomial outbreaks associated with this genotype in our hospital. The experiments were repeated independently three times. These data were expressed as the mean ± standard deviation (SD), two groups with significant differences were marked with * P < 0.05, and * * P < 0.01.
